Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users

Substance Use and Misuse

Volumn 40, Issue 8, 2005, Pages 1153-1167

  Wood, Evan ^a,b,d,e   Li, Kathy ^a   Palepu, Anita ^a,b,f   Marsh, David C ^c,g   Schechter, Martin T ^a,b,j   Hogg, Robert S ^a,b,h,i   Montaner, Julio S G ^a,b,j   Kerr, Thomas ^a,b,d,k  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e Canadian HIV/AIDS Legal Network   (Canada)

^f CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^g Interdisciplinary Health Research Team on Illicit Opiate Dependence   (Canada)

^h Drug Treatment Program   (Canada)

ⁱ Population Health Program

^j Canadian HIV Trials Network   (Canada)

^k Canadian HIV/AIDS Legal Network ^*  (Canada)

more..

Author keywords

Addiction treatment; HIV AIDS; Injection drug use

Indexed keywords

COCAINE; DIAMORPHINE; ILLICIT DRUG;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; DEMOGRAPHY; DRUG DEPENDENCE TREATMENT; DRUG USE; EPIDEMIC; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; NEEDLE EXCHANGE PROGRAM; POPULATION RISK; PRIORITY JOURNAL; SOCIOECONOMICS;

ADULT; BRITISH COLUMBIA; COHORT STUDIES; DEMOGRAPHY; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV SEROPOSITIVITY; HUMANS; MALE; NEEDLE-EXCHANGE PROGRAMS; POPULATION GROUPS; SOCIAL CLASS; SOCIAL JUSTICE; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 23044459892     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1081/JA-200042287     Document Type: Article

References (42)

1. 2001 Report of the Auditor General of Canada Chapter 11-Illicit Drugs: The Federal Government's Role. Office of the Auditor General of Canada. Available: http://www.oag-bvg.gc.ca/domino/reports.nsf/html/01menu_e.html. (Accessed January, 2002).
2. Alford, G. S., Koehler, R. A., Leonard, J. (1991). Alcoholics Anonymous-Narcotics Anonymous model inpatient treatment of chemically dependent adolescents: a 2-year outcome situdy. J. Stud. Alcohol. 52(2):118-126.
3. American Society of Addiction Medicine. (1994). Public policy statement on national drug policy. J. Addict. Dis. 13(4):231-234.
4. Bellm, J. (1999). Needle-exchange programmes are not the answer [letter; comment]. Lancet 353(9165):1657-1661.
5. Cartwright, W. S. (1988). Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Evaluation Review 22(5):609-636.
6. Collins, C., Coates, T. J. (2000). Science and health policy: can they cohabit or should they divorce? Am. J. Public Health 90(9):1389-1390.
7. Coutinho, R. A. (2000). Needle exchange, pragmatism, and moralism. Am. J. Public Health 90(9):1387-1388.
8. Cox, D. R. (1972). Regression models and life tables. J. Royal Stat. Soc. B 34:187-202.
9. Craib, K. J., Spittal, P. M., Wood, E., Laliberte, N., Hogg, R. S., Li, K., et al. (2003). Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 168(1):19-24.
10. Crits-Christoph, P., Siqueland, L., Blaine, J., Frank, A., Luborsky, L., Onken, L. S., et al. (1999). Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch. Gen. Psychiatry 56(6):493-502.
11. Des Jarlais, D. C. (2000). Research, politics, and needle exchange. Am. J. Public Health 90(9):1392-1394.
12. Des Jarlais, D. C., Marmor, M., Paone, D., Titus, S., Shi, Q., Perlis, T., et al. (1996). HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 348(9033):987-991.
13. Des Jarlais, D. C., Paone, D., Milliken, J., Turner, C. F., Miller, H., Gribble, J., et al. (1999). Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 353(9165):1657-1661.
14. Drake, S. (1998). Self-report among injecting drug users: a review. Drug Alcohol Depend. 51:253-263.
15. Hartel, D. M., Schoenbaum, E. E. (1998). Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Reports 113(Suppl 1):107-115.
16. Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., Bigelow, G. E. (2000). A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N. Engl. J. Med. 343(18):1290-1297.
17. Magura, S. (2000). Introduction: program quality in substance dependency treatment. Subst. Use Misuse 35(12-14):1617-1627.
18. Miller, C. L., Johnston, C., Spittal, P. M., Li, K., Laliberte, N., Montaner, J. S., et al. (2002). Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 36(3):737-742.
19. Miller, C. L., Tyndall, M., Spittal, P., Li, K., Palepu, A., Schechter, M. T. (2002). Risk-taking behaviors among injecting drug users who obtain syringes from pharmacies, fixed sites, and mobile van needle exchanges. J. Urban Health 79(2):257-265.
20. Moss, A. R. (2000). Epidemiology and the politics of needle exchange. Am. J. Public Health 90(9):1385-1387.
21. O'Shaughnessy, M. V., Montaner, J. S., Strathdee, S., Schechter, M. T. (1998). Deadly public policy. Int. Conf. AIDS. 12:982 (abstract no. 44233).
22. Palepu, A., Strathdee, S. A., Hogg, R. S., Anis, A. H., Rae, S., Cornelisse, P. G., et al. (1999). The social determinants of emergency department and hospital use by injection drug users in Canada. Journal of Urban Health 76(4):409-418.
23. Palepu, A., Tyndall, M. W., Leon, H., Muller, J., O'Shaughnessy, M. V., Schechter, M. T., et al. (2001). Hospital utilization and costs in a cohort of injection drug users. CMAJ 165(4):415-420.
24. Rehm, J., Gschwend, P., Steffen, T., Gutzwiller, F., Dobler-Mikola, A., Uchtenhagen, A. (2001). Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 358(9291):1417-1423.
25. Rydell, C. P., Caulkins, J. P., Everingham, S. E. (1996). Enforcement or treatment? Modeling the relative efficacy of alternatives for controlling cocaine. Operations Research 44(5):687-695.
26. Schechter, M. T (2002). Science, ideology, and needle exchange programs. Annals of the American Academy of Political and Social Science 582:94-101.
27. Schechter, M. T., Strathdee, S. A., Cornelisse, P. G., Currie, S., Patrick, D. M., Rekart, M. L., et al. (1999). Do needle exchange programmes increase the spread of HIV among injection drug users?: An investigation of the Vancouver outbreak. AIDS 13(6):F45-F51.
28. Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., et al. (2000). Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial [see comments]. JAMA 283(10):1303-1310.
29. Strathdee, S. A., Galai, N., Safaeian, M., Celentano, D. D., Vlahov, D., Lisette, J., et al. (2001). Sex differences in risk factors for HIV seroconversion among injection drug users: a ten year perspective. Archives of Internal Medicine 161:1281-1288.
30. Strathdee, S. A., Patrick, D. M., Currie, S. L., Cornelisse, P. G., Rekart, M. L., Montaner, J. S., et al. (1997). Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 11(8):F59-F65.
31. Tyndall, M. W., Currie, S., Spittal, P., Li, K., Wood, E., O'Shaughnessy, M. V., et al. (2003). Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 17(6):887-893.
32. Vlahov, D. (2000). The role of epidemiology in needle exchange programs. Am. J. Public Health 90(9):1390-1392.
33. Wall, R., Rehm, J., Fischer, B., Brands, B., Gliksman, L., Stewart, J., et al. (2000). Social costs of untreated opioid dependence. J. Urban Health 77(4):688-722.
34. Wenger, L. D., Rosenbaum, M. (1994). Drug treatment on demand-not. Journal of Psychoactive Drugs 26(1):1-11.
35. Wood, E., Kerr, T., Montaner, J. S., Strathdee, S. A., Wodak, A., Hankins, C. A., et al. (2004). Rationale for evaluating North America's first medically supervised safer injecting facility. Lancet Infect. Dis. 4:301-306.
36. Wood, E., Kerr, T., Spittal, P. M., Li, K., Small, W., Tyndall, M. W., et al. (2003). The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J. Acquir. Immune Defic. Syndr. 32(1):2-8.
37. Wood, E., Kerr, T., Spittal, P. M., Tyndall, M. W., O'Shaughnessy, M. V., Schlechter, M. T. (2003). The healthcare and fiscal costs of the illicit drug use epidemic: the impact of conventional drug control strategies and the impact of a comprehensive approach. BCMJ 45(3):130-136.
38. Wood, E., Montaner, J. S., Schechter, M. T., Tyndall, M. W., O'Shaughnessy, M. V., Hogg, R. S. (2003). Prevalence and correlates of untreated HIV-1 infection in the era of modern antiretroviral therapy. Journal of Infectious Diseases 188(8):1164-1170.
39. Wood, E., Spittal, P. M., Kerr, T., Small, W., Tyndall, M. W., O'Shaughnessy, M. Y., et al. (2003). Requiring help injecting as a risk factor for HIV infection in the Vancouver epidemic: implications for HIV prevention. Can. J. Public Health 94(5):355-359.
40. Wood, E., Tyndall, M. W., Spittal, P. M., Li, K., Anis, A. H., Hogg, R. S., et al. (2003). Supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ 168(2):165-169.
41. Wood, E., Tyndall, M. W., Spittal, P. M., Li, K., Hogg, R. S., Montaner, J. S., et al. (2002). Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 16(6):941-943.
42. Wood, E., Tyndall, M. W., Spittal, P., Li, K., R. S. H., O'Shaughnessy, M., et al. (2002). Needle exchange and difficulty with needle access during an ongoing HIV epidemic. International J. Drug Policy 13(2):95-102.